DEVELOPMENT AND VALIDATION OF A STABILITY INDICATING LIQUID CHROMATOGRAPHIC METHOD FOR THE SIMULTANEOUS ESTIMATION OF PAROXETINE AND CLONAZEPAM IN BULK AND ITS PHARMACEUTICAL FORMULATIONS
A novel stability indicating reversed-phase liquid chromatographic method has been developed and validated for simultaneous estimation of paroxetine and clonazepam in combined pharmaceutical dosage form. An Agilent zorbax sb-c18 (250mmx4.6mmx5 Âµm) column with the mobile phase containing 0.2 % Orthophosphoric acid and Methanol (60:40 v/v) was used. The flow rate was maintained at 0.8 ml/min, column temperature was 30Â°C and effluents were monitored by using a photodiode array detector at 270 nm. The retention times of paroxetine and clonazepam were found to be 3.478min and 3.964 min, respectively. Correlation co-efficient for paroxetine and clonazepam were found to be 0.99 and 0.99, respectively. The proposed method was validated with respect to linearity, accuracy, precision, specificity, and robustness. Recovery of paroxetine and clonazepam in formulations was found to be in a range of 97-103% and 97-103% respectively. Paroxetine and clonazepam were also subjected to the stress conditions of oxidative, acid, base, hydrolytic, thermal and photolytic degradation. The degradation products were well resolved from and peak purity test results confirmed that paroxetine and clonazepam peaks were homogenous and pure in all stress samples, thus proving stability-indicating power of the method. Due to its simplicity, rapidness and high precision, this method can be applied for regular analysis.
2. Knoeller J, Vogt-Schenkel R, Brett MA. A simple and robust high-performance liquid chromatography method for the determination of paroxetine in human plasma. J Pharm Biomed Anal 1995;13:635-8.
3. Athanasiou NV, Politou JA, Koupparis M, Spyropoulos J. Development and validation of an HPLC method, with fluorescence detection, for simultaneous determination of paroxetine and its metabolites in plasma. J Liq Chromatogr Relat Technol 2007;30:1641-55.
4. Wille SMR, Maudens KE, Van Peteghem CH, Lambert WEE. Development of a solid phase extraction for 13 new generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis. J Chromatogr A 2005;1098:1-2.
5. D Baldwin, J Bobes, DJ Stein, I Scharwachter, M Faure. "Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group". Br J Psychiatry 1999;175(2):120â€“6.
6. Browne TR. "Clonazepam. A review of a new anticonvulsant drug". Arch Neurol 1976;33(5):326â€“32.
7. J Arthur FS, Carl VP, Nancy M. Determination of Clonazepam and flunitrazepam in blood and urine by electron-capture GLC. J Pharm Sci 1974;63:520â€“7.
8. Kawahara K, Awaji T, Uda K, Sakai Y. Determination of four metabolites of dothiepin in urine by high-performance liquid chromatography. J Pharm Biomed Anal 1987;5:183â€“9.
9. Christopher J, James TS. Analysis of Clonazepam in a tablet dosage form using small bore HPLC. J Pharm Biomed Anal 1998;18:453â€“60.
10. Isabelle Forfar Bares, Fabienne Pehourcq, Christian Jarry. Development of a rapid RPâ€“HPLC method for the determination of clonazepam in human plasma. J Pharm Biomed Anal 2004;36:865-9.
11. The Indian Pharmacopoeia, The Indian Pharmacopoeia commission, Ghaziabad, 6th edition; 2010. p. 1111-4.
12. British Pharmacopoeia, British Pharmacopoeia Commission 2007;546:2444-5.
13. United state pharmacopoeia, Rockville, USP convention, Inc, 30th edition; 2007. p. 1795-7.
14. International Conference on Harmonization; Validation of Analytical Procedures: Text and methodology. ICH Q2R(1), Geneva; 2005.
15. Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances ICH, Q6A, Geneva; 1999.
16. Guidance for Industry on Analytical Procedures and methods Validation Chemistry: Manufacturing, and Controls Documentation (draft), FDA, Rockville, MD; 2000.
17. Stability Testing of New Drug Substances and Products, International Conference on Harmonization ICH, Q1A (R2), Geneva; 2003.
18. Stability Testing: Photostability Testing of New Drug Substances and Products, International Conference on Harmonization ICH, Q1B, Geneva; 1996.
19. Maheshwaran R. FDA Perspectives: scientific considerations of forced degradation studies in anda submissions. Pharm Technol 2012;36:73-80.
20. Snyder LR. Introduction to modern liquid chromatography, 3rd Ed. Newyork, Wiley; 2010.
21. Snyder LR, Kirkland JJ, Glajch JL. Practical HPLC Method Development, 2nd ed. New York, Wiley; 1997.
22. R Kakde, D Satone, N Bawane. HPTLC method for simultaneous analysis of escitalopram and clonazepam in pharmaceutical preparation. J Planar Chromatography 2009;22(6):417-20.
23. Christine Greiner, Christoph Hiemke, Wolfgang Bader, Ekkehard Haen. Determination of citalopram and escitalopram together with their active main metabolites desmethyl(es-) citalopram in human serum by column-switching high performance liquid chromatography (HPLC) and spectrophotometric detection. J Chromatogr B 2007;848:391â€“4.